Heron Therapeutics is projected to report Q3 2026 revenue of $52.4 million and an EPS loss of $0.03, with the stock currently trading at $2.75 against a $6.50 average analyst price target. Investors are primarily focused on ZYNRELEF net product sales for the Q3 2026 period as a barometer for the company's penetration into the surgical pain market.
The quarter follows significant efforts to optimize the commercial structure and maximize the impact of the NOPAIN Act reimbursement tailwinds. Strong volume growth in ZYNRELEF is essential for Heron to validate its path toward sustained profitability and positive cash flow by the end of the fiscal year.